End Point
DISEASE
The primary outcome was disease activity at 3 and 9 months after initiating treatment. The average treatment effect (ATE) was defined as the difference in mean DAS28-CRP among patients receiving TOF compared with those receiving ADA at 3 and 9 months.These time points were selected because joint counts and pathologic markers are assessed for government reimbursement at 3 and 9 months. American College of Rheumatology response of at least 50% was used in the trial of ADA and TOF.